Premium
BioMarin Pharmaceutical Inc (BMRN)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition ... BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe. Show more
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court PR Newswire SAN RAFAEL, Calif., Jan. 13, 2025 SAN RAFAEL, Calif., Jan. 13, 2025 /PRNewswire/...
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA PR Newswire SAN RAFAEL, Calif., Jan. 6, 2025 SAN...
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE...
BioMarin to Participate in Three Upcoming Investor Conferences PR Newswire SAN RAFAEL, Calif., Nov. 6, 2024 UBS Global Healthcare Conference on November 12 at 11:00 am PSTJefferies London...
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook PR Newswire SAN RAFAEL, Calif., Oct. 29...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.26 | 2.02898550725 | 62.1 | 64.33 | 61.23 | 1440436 | 62.90185077 | CS |
| 4 | -3.57 | -5.33393097266 | 66.93 | 69.7 | 60.63 | 1791219 | 63.33228277 | CS |
| 12 | -3.85 | -5.72831423895 | 67.21 | 69.7 | 60.63 | 1533516 | 64.61808971 | CS |
| 26 | -16.88 | -21.036889332 | 80.24 | 94.85 | 60.63 | 1682295 | 71.920836 | CS |
| 52 | -24.4 | -27.8030993619 | 87.76 | 94.85 | 60.63 | 1833660 | 78.42506496 | CS |
| 156 | -23.76 | -27.2727272727 | 87.12 | 117.77 | 60.63 | 1497436 | 85.6871956 | CS |
| 260 | -20.1 | -24.0833932423 | 83.46 | 131.945 | 60.63 | 1479525 | 85.59916768 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
